P. Marcellin Et Al. , "Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B," 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , vol.42, San-Francisco, Costa Rica, 2005
Marcellin, P. Et Al. 2005. Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B. 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , (San-Francisco, Costa Rica).
Marcellin, P., Bonino, F., Lau, G., Farci, P., Yurdaydin, C., Piratvisuth, T., ... Jin, R.(2005). Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B . 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica
Marcellin, P Et Al. "Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B," 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 2005
Marcellin, P Et Al. "Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B." 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , San-Francisco, Costa Rica, 2005
Marcellin, P. Et Al. (2005) . "Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B." 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={P Marcellin Et Al. }, title={Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative chronic hepatitis B}, congress name={56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases}, city={San-Francisco}, country={Costa Rica}, year={2005}}